At the level of DNA epigenetic modification, DNMT3a has been shown to promote colorectal cancer progression and oxaliplatin resistance by directly binding to the promoter regions of DAB2IP and MEIS122, 31. The gene discussed is DNMT3A; the disease is colorectal cancer.